GLP-1 hair shedding and 'Ozempic face': what's the drug and what's the weight loss
Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board
- Hair loss is a labelled side effect: about 3% to 6% of people on Wegovy or Zepbound in trials, against about 1% on placebo, and mostly women. Both labels say it was associated with weight reduction.
- The pattern looks like telogen effluvium, excessive shedding that drugs, trauma or physiological stress can trigger. After bariatric surgery, shedding peaked at three months and improved slightly by six.
- 'Ozempic face' is not a medical diagnosis. Rapid weight loss has been implicated in facial ageing on these drugs; whether they do anything more is unproven.
What the labels count
Hair loss appears in the most-common side effects listed on both the Wegovy and Zepbound labels, and each gives numbers from its weight-loss trials 1 2:
| Label and trials | Hair loss on the drug | On placebo | By sex (drug) |
|---|---|---|---|
| Wegovy 2.4 mg, adult weight-loss trials | 3.3% | 1% | 4% of women, 0.9% of men |
| Wegovy 7.2 mg, adult trials | 5.8% | 1.0% | 8.4% of women, 0.2% of men |
| Wegovy 2.4 mg, adolescent trial | 4% | 0% | Not given |
| Zepbound 5, 10 and 15 mg, adult trials | 5%, 4% and 5% | 1% | 7.1% of women, 0.5% of men |
Two details stand out. First, both labels use the same words: hair loss adverse reactions were associated with weight reduction 1 2. Second, the risk is concentrated in women in every row that reports sex. The effect is rarely serious enough to stop treatment: no Zepbound-treated patient in the main trials stopped for hair loss, and on Wegovy 7.2 mg one person stopped permanently and five had their dose reduced 2 1. The higher dose of semaglutide came with more hair loss: 5.8% on 7.2 mg against 3.3% on 2.4 mg in the same trials 1.
Can you compare the drugs?
It is tempting to read the table as saying Zepbound causes more hair loss than Wegovy, or the reverse. Both labels warn against exactly that: they say adverse reaction rates from one drug's trials cannot be directly compared with rates from another drug's trials, because trials run under widely varying conditions 1 2. The trials enrolled different people, recorded side effects in different ways and produced different amounts of weight loss. What can be said is that within each drug's own trials, hair loss was several times more common than on placebo, and in Wegovy's trials the higher dose came with more hair loss 1.
Why women report it more
Every figure on both labels shows hair loss reported far more often by women than men: 7.1% against 0.5% on Zepbound, and 8.4% against 0.2% on the highest Wegovy dose 2 1. The same pattern appears after weight-loss surgery, where female sex independently predicted shedding 3, and a review of telogen effluvium notes that excessive shedding is usually complained about by women and is often found together with pattern hair loss 4. Why women report it more on these drugs has not been studied. For women already experiencing hair thinning, it is worth raising before starting treatment so that other causes can be checked first.
Why weight loss makes hair shed: telogen effluvium
Telogen effluvium is excessive shedding of hair and one of the most common causes of hair loss. Drugs, trauma and emotional or physiological stress can set it off; changes in the hair growth cycle are the proposed mechanism; it can be acute or chronic; and treatment starts with identifying and removing the cause (review) 5.
The timeline is well documented after bariatric surgery, the closest comparison to drug-induced weight loss. In a 2026 study of 261 patients after two types of weight-loss surgery, hair loss on a standard pull test rose significantly at three months, peaked there, and improved slightly by six (not a significant change from three months); low iron and female sex were the strongest predictors, and low baseline zinc also predicted it 3. The authors describe it as a temporary and reversible complication when nutrition is monitored and supplemented 3. Whether the same course applies to weight loss on a GLP-1 drug has not been measured.
Is it the drug or the weight loss?
That is the hardest question, and the honest answer is that the evidence leans towards weight loss without ruling out a direct effect. In favour of weight loss: the labels explicitly link hair loss to weight reduction, rates rise with the dose that produces more weight loss, and a higher Wegovy dose came with more of it 1 2. Against a simple story: an analysis of the FDA's adverse event reports found alopecia among the five most common skin reactions reported with GLP-1 drugs, and reported more often when the drugs were used for type 2 diabetes than for weight management 6. Spontaneous reports cannot establish cause, and people with diabetes differ in many ways, but the finding means the question is not closed.
A 2025 review proposed that GLP-1 receptors on skin cells might affect skin and fat directly 7, though that work is laboratory-based and has not shown an effect on human hair. No randomised trial has compared hair loss on a GLP-1 drug with the same weight loss achieved another way, which is the comparison that would settle it.
What the trial numbers cannot tell you
Trial figures have limits worth knowing. The labels report hair loss as adverse reactions 1 2, not as hair counts or scalp photographs, so mild shedding may have been missed and some reports may have had other causes. The trials say little about whether shedding recurs with further dose increases or after stopping and restarting, and they enrolled adults with obesity, or overweight with a related condition, and adolescents with obesity 1 2. The figures are a fair guide to the average experience on the approved drugs at the approved doses, not a promise for any individual.
'Ozempic face'
'Ozempic face' is a popular term, not a diagnosis, for a face that looks hollow, loose or older after weight loss on these drugs. A 2025 systematic review of the plastic surgery literature found 23 articles discussing GLP-1 drugs, describing changes that resemble advanced ageing and the surgical and non-surgical options used to treat them, and linked online searches for the term to rising searches for face fillers and plastic surgeons 8. Its abstract reports no measured comparison of facial change on a GLP-1 drug with facial change after the same weight loss by diet or surgery.
A 2025 review notes that the rapid weight loss seen with these drugs has been implicated in facial ageing, and argues that they might also affect fat-derived stem cells and skin fibroblasts directly 7; that second idea has not been shown in people. For now, the evidence supports treating 'Ozempic face' as the face of significant weight loss, with a possible drug contribution unproven.
Muscle, protein and the speed of loss
Part of what people notice is the loss of muscle and other lean tissue along with fat. Weight-loss drugs reduce both, and the balance matters for strength and appearance. A body-composition substudy of retatrutide, a newer drug in trials, in people with type 2 diabetes found fat mass falling by up to about a quarter at 36 weeks, with the proportion of lean mass lost to weight lost similar to other obesity treatments 9. After weight-loss surgery, low iron and zinc were the nutritional factors linked to shedding 3.
What helps
For hair, the main points are patience and checking for fixable causes. Treatment of telogen effluvium starts with finding and removing the cause 5, it is often found together with pattern hair loss 4, and after weight-loss surgery low iron and zinc were linked to shedding 3, so a doctor may check those. Approved treatments for pattern hair loss exist; our article on peptides for hair loss explains why peptide products are not among the proven ones.
For the face, the options described in the plastic surgery literature range from fillers to surgery 8. Anyone considering cosmetic treatment after GLP-1 weight loss may want to wait until their weight is stable, because further loss changes the result.
Do not stop or reduce a prescribed GLP-1 drug because of hair shedding without talking to your prescriber. The labels report that few people stop for it 2 1.
When to see a doctor
See a doctor or dermatologist if shedding goes on longer than the few months seen after weight-loss surgery 3, comes in patches, or comes with other symptoms, since telogen effluvium can be chronic and can sit alongside other hair loss 5 4. Bring a note of when you started the drug, each dose change and when shedding began.
Compounded and research products
Everything above comes from trials of the approved drugs at known doses. People using compounded or research semaglutide, tirzepatide or retatrutide have less certainty about the dose they are actually getting. Our guide to compounded, branded and research tirzepatide sets out the differences, and the GLP-1 transition hub covers changing treatment safely.
Frequently asked questions
Does Ozempic cause hair loss?
Hair loss is a listed side effect of semaglutide at weight-loss doses: in Wegovy's trials it was reported by 3.3% on 2.4 mg against 1% on placebo, mostly women. The label says it was associated with weight reduction.
Does tirzepatide cause hair loss?
In Zepbound's weight-loss trials, hair loss was reported by 4% to 5% of patients against 1% on placebo, 7.1% of women and 0.5% of men. No Zepbound-treated patient stopped treatment because of it.
Is GLP-1 hair loss permanent?
The pattern fits telogen effluvium; after weight-loss surgery, shedding peaked at three months and improved slightly by six. Shedding that lasts longer or comes in patches should be checked by a doctor.
What is Ozempic face?
A popular term for the hollow or older look some people develop after large weight loss on GLP-1 drugs. It is not a diagnosis, and there is little measured evidence that the drugs affect the face beyond the weight loss itself.
Related on Grey Peptides
Sources
- Novo Nordisk. Wegovy (semaglutide) US prescribing information, sections 6.1 (hair loss) and the adverse reaction tables (DailyMed set ee06186f, version 19, effective June 18, 2026); SPL re-read October 27, 2026. DailyMed
- Eli Lilly. Zepbound (tirzepatide) US prescribing information, section 6.1, Table 1 and hair loss text (DailyMed set 487cd7e7, version 40, effective August 28, 2026); SPL re-read October 27, 2026. DailyMed
- Chinisaz, F., et al. (2026). Comparative Analysis of Postoperative Hair Loss and Micronutrient Deficiencies After One-Anastomosis Gastric Bypass Versus Sleeve Gastrectomy. Obes Surg, 36(4), 1804-1813. PMID: 41894131
- Rebora, A. (2019). Telogen effluvium: a comprehensive review. Clin Cosmet Investig Dermatol, 12, 583-590. PMID: 31686886
- Asghar, F., et al. (2020). Telogen Effluvium: A Review of the Literature. Cureus, 12(5), e8320. PMID: 32607303
- Daniel, S., et al. (2025). A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies. J Drugs Dermatol, 24(4), 413-415. PMID: 40196945
- Paschou, I. A., et al. (2025). GLP-1RA and the possible skin aging. Endocrine, 89(3), 680-685. PMID: 40498168
- Daneshgaran, G., et al. (2025). "Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions. Aesthet Surg J Open Forum, 7, ojaf056. PMID: 40626110
- Coskun, T., et al. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol, 13(8), 674-684. PMID: 40609566
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead